As of 2021, BV has been approved for the treatment of RR cHL, ND, and RR CD30+ systemic anaplastic large cell lymphoma and RR CD30+ cutaneous T-cell lymphoma [37,39,40,41,42]. The gene discussed is TNFRSF8; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.